Immunocore Holdings plc
IMCRNASDAQHealthcare● Active
$27.82
$-0.47(-1.66%)
Market Cap$1.4B
P/E Ratio—
52W High$40.715
52W Low$27.555
Immunocore Holdings plc (IMCR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IMCR · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.30B | $0.25B | $0.20B | $0.14B | $0.03B |
| Cost of Revenue | $0.01B | $0.01B | $0.00B | $0.01B | $0.00B |
| Gross Profit | $0.29B | $0.24B | $0.20B | $0.14B | $0.03B |
| Gross Margin %(computed) | 97.91% | 97.76% | 99.58% | 96.33% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.20B | $0.18B | $0.13B | $0.08B | $0.07B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.33B | $0.30B | $0.24B | $0.18B | $0.16B |
| Operating Income | ($0.03B) | ($0.06B) | ($0.05B) | ($0.04B) | ($0.13B) |
| Operating Margin %(computed) | -11.34% | -22.70% | -23.91% | -29.66% | -478.53% |
| Interest Income | $0.02B | $0.03B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.02B | $0.00B | $0.01B | $0.01B |
| Income Before Tax | ($0.01B) | ($0.04B) | ($0.05B) | ($0.03B) | ($0.13B) |
| Income Tax Expense | $0.01B | ($0.00B) | ($0.00B) | $0.01B | $0.00B |
| Net Income | ($0.03B) | ($0.04B) | ($0.04B) | ($0.04B) | ($0.13B) |
| Net Margin %(computed) | -8.88% | -16.45% | -22.17% | -30.13% | -493.45% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.53 | $-1.02 | $-0.89 | $-0.95 | $-3.13 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.04B |
| EBITDA | $0.00B | ($0.04B) | ($0.04B) | ($0.04B) | ($0.12B) |
| EBITDA Margin %(computed) | 0.13% | -15.53% | -20.71% | -26.59% | -456.95% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Immunocore Holdings plc data
About Immunocore Holdings plc (IMCR) Income Statement
Immunocore Holdings plc (IMCR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IMCR reported revenue of $0.30B, gross profit of $0.29B (gross margin 97.91%), and net income of ($0.03B) — a net profit margin of -8.88%.
Frequently asked questions
IMCR · 4 questionsImmunocore Holdings plc (IMCR) reported revenue of $0.30B for 2025, up 20.0% year-over-year.
IMCR revenueIMCR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08